Therapeutic benefits of infrared (810-nm) diode laser macular grid photocoagulation in prophylactic treatment of nonexudative age-related macular degeneration

Olk, R. Joseph; Friberg, Thomas R.; Stickney, Kristin L.; Akduman, Levent; Wong, Keye L.; Chen, Melvin C.; Levy, Marc H.; Garcia, Charles A.; Morse, Lawrence S.

doi:10.1016/s0161-6420(99)90487-6

Cited by 83 publications

(59 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[8][9][10][11][12][13] These trials confirmed the anecdotal observations that laser photocoagulation to the macula caused the disappearance of drusen. Color fundus imaging confirmed these observations.…”

Section: Introductionsupporting

confidence: 71%

“…During the study, blood samples for pharmacokinetic and complement factor screening were drawn and analyzed in a masked fashion at baseline and at every planned visit at weeks 1, 2, 3, 4,6,8,10,12,14,16,18,20,22,24,26,28,38, and 52. Alexion Pharmaceuticals laboratory measured soluble C5b-9 and performed a hemolytic assay for C5 activity.…”

Section: Pharmacokinetic and Complement Factors Analysismentioning

confidence: 99%

See 1 more Smart Citation

Change in Drusen Volume as a Novel Clinical Trial Endpoint for the Study of Complement Inhibition in Age-related Macular Degeneration

Filho¹,

Yehoshua²,

Gregori³

et al. 2014

Ophthalmic Surg Lasers Imaging Retina

View full text Add to dashboard Cite

BACKGROUND AND OBJECTIVE:To evaluate the change in drusen volume following treatment with eculizumab, a systemic inhibitor of complement component 5. PATIENTS AND METHODS:Single-center, prospective, randomized, double-masked clinical trial. Patients were randomized 2:1 to receive intravenous eculizumab or placebo over 26 weeks. Main outcome measure: decrease in drusen volume of at least 50% at 26-week follow-up. RESULTS:Mean drusen cube root volumes were 0.49 mm and 0.47 mm (P = .64) at baseline and 0.51 mm and 0.42 mm (P = .17) at 26 weeks in the eculizumab and placebo groups, respectively. In the placebo group, one eye had a decrease in drusen volume of at least 50% and two eyes developed neovascularization through 26 weeks. CONCLUSION:Systemic complement inhibition with eculizumab did not significantly reduce drusen volume. Drusen growth was dependent on the number of complement at-risk alleles. Future trials should consider the use of a composite clinical trial endpoint in which efficacy is defined by the treatment's ability to prevent drusen growth, neovascularization, and the formation of geographic atrophy over 1 year.

show abstract

Section: Introductionsupporting

confidence: 71%

Section: Pharmacokinetic and Complement Factors Analysismentioning

confidence: 99%

Change in Drusen Volume as a Novel Clinical Trial Endpoint for the Study of Complement Inhibition in Age-related Macular Degeneration

Filho¹,

Yehoshua²,

Gregori³

et al. 2014

Ophthalmic Surg Lasers Imaging Retina

View full text Add to dashboard Cite

show abstract

“…The development of neovascular membrane was observed in patients who received higher intensity laser treatment; this process was promoted by the migration of endothelial cells of the choriocapillaris, as well as other endothelial growth factors and fibroblasts, after the tearing of Bruch's membrane (25) . Photocoagulation did not prove to be beneficial in the prevention of neovascularization in PED, when compared to the control group of another study (26) . During a report of the one-year follow-up of a case of symptomatic and progressive serous PED, the micropulse laser treatment resulted in the flattening of the lesion and visual acuity improvement (27) .…”

Section: Discussionmentioning

confidence: 65%

Grid laser photocoagulation in the treatment of serous avascular pigment epithelial detachment in age-related macular degeneration

Filho¹,

Moreira²,

Malafaia³

et al. 2014

Arquivos Brasileiros De Oftalmologia

View full text Add to dashboard Cite

Purpose: Describe the outcomes of thermal laser photocoagulation in three cases of retinal pigment epithelium detachment associated to age-related macular degeneration. Methods: Three patients with avascular retinal pigment epithelium detachment were treated with green diode laser photocoagulation. Mild macular grid laser application, similar to the treatment of diabetic macular edema was performed after an unsuccessful intravitreal anti-angiogenic treatment. Results: After one year of the laser treatment, two cases reached anatomic resolution, with complete absorption of sub-epithelium serum fluid and improvement of the visual acuity. There was stability of the visual acuity and sub-epithelium fluid reduction, which, however, was partial in the third case. No complications related to the treatment occurred until the conclusion of this study. Conclusions: Macular photocoagulation in grid pattern produced regression of avascular serous pigment epithelium detachment associated with age-related macular degeneration in a short follow-up period. Although long term prospecti ve studies with an increased sample are necessary, it is a method that can be applied in selected patients, with absence of sub-retinal neovascularization or sub-epithelium fibrovascular component.

show abstract

“…Despite several other similar studies in progress, we are only the second group to express concern regarding laser-induced CNV. [4][5][6][7][8][9][10] A further report from the CNV Prevention Trial described a relation between higher-intensity laser treatment on earlier onset of CNV when compared to the low-intensity group. 11 We were unable to perform a similar analysis for two reasons.…”

Section: Discussionmentioning

confidence: 99%

Prophylactic laser treatment appears to promote choroidal neovascularisation in high-risk ARM: results of an interim analysis

Owens

Bunce

Brannon

et al. 2003

Eye

View full text Add to dashboard Cite

Therapeutic benefits of infrared (810-nm) diode laser macular grid photocoagulation in prophylactic treatment of nonexudative age-related macular degeneration

Cited by 83 publications

References 16 publications

Change in Drusen Volume as a Novel Clinical Trial Endpoint for the Study of Complement Inhibition in Age-related Macular Degeneration

Change in Drusen Volume as a Novel Clinical Trial Endpoint for the Study of Complement Inhibition in Age-related Macular Degeneration

Grid laser photocoagulation in the treatment of serous avascular pigment epithelial detachment in age-related macular degeneration

Prophylactic laser treatment appears to promote choroidal neovascularisation in high-risk ARM: results of an interim analysis

Contact Info

Product

Resources

About